Form 4: Viking Therapeutics CFO Greg Zante Reports Stock Transactions
SEC Form 4 Filing
Chief Financial Officer of Viking Therapeutics, Greg Zante, reports acquisition and disposal of company stock related to vesting of performance restricted stock units.
Summary
- Greg Zante, CFO of Viking Therapeutics, reported transactions involving the company's common stock on March 27, 2024.
- Zante acquired 31,667 shares of common stock at $0.00 related to the vesting of performance restricted stock units.
- He also disposed of 16,610 shares at $83.34 to cover tax withholding obligations.
- Following these transactions, Zante directly owns 207,361 shares of Viking Therapeutics common stock.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing detailing stock transactions. The sentiment is neutral as it simply reports facts. The vesting of performance restricted stock units is a slightly positive sign.
Positives
- The vesting of performance restricted stock units indicates the achievement of a non-financial performance goal by the company.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors.
Key Dates
| Date | Description |
|---|---|
| January 3, 2023 | Date of grant for the performance restricted stock unit award. |
| March 27, 2024 | Date of stock transactions and vesting of performance restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.